Form 4: Aquestive Therapeutics SVP Withholds Shares for Tax on RSU Vesting

Aquestive Therapeutics, Inc.'s Senior Vice President of Sales and Marketing, Sherry Korczynski, reported a routine transaction involving the withholding of 2,714 common shares to cover tax obligations related to the vesting of Restricted Stock Units.

Summary

• Sherry Korczynski, SVP Sales and Marketing at Aquestive Therapeutics, Inc. (AQST), reported a transaction on June 9, 2025.
• The transaction involved the disposition of 2,714 shares of common stock at a price of $3.54 per share.
• These shares were withheld by the issuer to satisfy the reporting person's tax withholding obligation in connection with the vesting of previously granted Restricted Stock Units (RSUs).
• Following this transaction, Sherry Korczynski beneficially owns 156,858 shares of Aquestive Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, non-discretionary transaction (tax withholding on RSU vesting) and does not indicate any change in management's view of the company or its prospects.

Future Outlook

This document, an SEC Form 4, does not provide information regarding the company's future outlook or guidance.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the withholding of shares for tax purposes upon RSU vesting. It does not provide broader industry context or trends, but is a common occurrence for executives receiving equity compensation in publicly traded biopharmaceutical companies.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not reflect a discretionary sale by the insider.

Key Dates

Keywords

Aquestive Therapeutics, AQST, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Common Stock, Biopharmaceutical, Pharmaceutical